Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today

NEW YORK (TheStreet) -- Catalyst Pharmaceutical Partners  (CPRX) shares are up 14.2% to $3.41 on Tuesday after ROTH Capital raised the company's price target to $6 from $5 and reiterated its "buy" rating.

The upgraded outlook stems from Catalyst's positive phase III study results of Firdapse, a treatment for Lamber-Eaton Myasthenic Syndrome.

Some analysts believe that this news will lead to a prohibitive price tag of between $60,000 and $80,000 a year for the treatment.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet's Adam Feuerstein discusses the implications of the study results in depth here.

CPRX Chart CPRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call